The severe asthma treatment Fasenra Prefilled Syringe 30 mg (benralizumab, AZ) and multiple myeloma treatment Xpovio Tab 20 mg (selinexor, Antengene) may be reimbursed as early as July.

The companies that own the two products have completed drug pricing negotiations with the National Health Insurance Service, and are waiting for them to be reported to the Ministry of Health and Welfare’s Health Insurance Policy Review Committee.

According to industry sources on the 17th, the companies reached an agreement in the latest round of drug price negotiations for Fasenra and Xpovio.

Fasenra is a treatment for severe eosinophilic asthma and will be reimbursed through the